Effects of orally active taxanes on P-glycoprotein modulation and colon and breast carcinoma drug resistance

Journal of the National Cancer Institute

Volumn 93, Issue 16, 2001, Pages 1234-1245

  Vredenburg, Michael R ^a   Ojima, Iwao ^b   Veith, Jean ^a   Pera, Paula ^a   Kee, Kristin ^a   Cabral, Fernando ^c   Sharma, Amarnath ^a   Kanter, Peter ^a   Greco, William R ^a   Bernacki, Ralph J ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; DOXORUBICIN; GLYCOPROTEIN P; IDN 5102; IDN 5106; IDN 5111; IDN 94004; IDN 94042; IDN 94045; IDN 95048; IDN 95049; ORTATAXEL; PACLITAXEL; RHODAMINE 123; TAXANE DERIVATIVE; TRA 96023; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOMA; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER TRANSPLANTATION; COLON CARCINOMA; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG ACTIVATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RESISTANCE; DRUG RETENTION; DRUG STRUCTURE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VIVO STUDY; INCUBATION TIME; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCID MOUSE; STATISTICAL ANALYSIS; XENOGRAFT;

EID: 0035881082     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/93.16.1234     Document Type: Article

References (61)

1. Paclitaxel (Taxol)
2. The taxoids. Comparative clinical pharmacology and therapeutic potential
3. Paclitaxel: An update of its use in the treatment of metastatic breast cancer and ovarian and other gynecological cancers
4. Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms
5. Cytotoxic studies of paclitaxel (Taxol) in human tumor cell lines
6. Mechanism of mitotic block and inhibition of cell proliferation by Taxol at low concentrations
7. Taxol-induced polymerization of purified tubulin. Mechanism of action
8. Promotion of microtubule assembly in vitro by Taxol
9. Taxol stabilizes microtubules in mouse fibroblast cells
10. Taxol binds to polymerized tubulin in vitro
11. Taxol assembles tubulin in the absence of exogenous guanosine 5′-triphosphate or microtubule-associated proteins
12. Taxol binds to cellular microtubules
13. Taxol-induced mitotic block rapid onset of a p53 independent apoptotic pathway
14. Tubulin alterations in Taxol-induced apoptosis parallel those observed with other drugs
15. Characterizations of paclitaxel-induced apoptosis and altered gene expression in human breast cancer cells
16. Possible mechanism of paclitaxel-induced apoptosis
17. Molecular effects of paclitaxel: Myths and reality
18. Paclitaxel (Taxol): Mechanisms of resistance
19. Taxol-dependent mutants of Chinese hamster ovary cells with alterations in α- and β-tubulin
20. Expression of a full-length cDNA for the human "MDR1" Gene confers resistance to colchicine, doxorubicin, and vinblastine
21. Characterization of a human myeloid leukemia cell line highly resistant to Taxol
22. Mechanisms of multidrug resistance in human tumor cells. The roles of P-glycoprotein, DNA topisomerase II, and other factors
23. Syntheses and structure-activity relationships of the second-generation antitumor taxoids: Exceptional activity against drug-resistant cancer cells
24. Syntheses and structure-activity relationships of taxoids derived from 14β-hydroxy-10 deacetylbaccatin III
25. Synthesis and structure-activity relationships of nonaromatic taxoids: Effects of alkyl and alkenyl ester groups on cytotoxicity
26. New taxanes as highly efficient reversal agents for multidrug resistance in cancer cells
27. New weapons in the fight against cancer
28. Designing taxanes to treat multidrug-resistant tumors
29. Anti-proliferative activity of a ner class of taxanes (14β-hydroxy-10-deacetylbaccatin III derivatives) on multidrug-resistance-positive human cancer cells
30. A novel taxane with improved tolerability and therapeutic activity in a panel of himan tumor xenografts
31. IDN5109, a taxane with oral bioavailability and potent antitumor activity
32. Oral efficacy and bioavailability of a novel taxane
33. MDA435/LCC6 WT and MDA435/LCC6mdr1: Ascites models of human breast cancer
34. A human cell line from a pleural effusion derived from a breast carcinoma
35. Cellular genes analogous to retroviral onc genes are transcribed in human tumour cells
36. Characterization of a newly derived human sarcoma cell line (HT-1080)
37. Isolation of amplified and overexpressed DNA sequences from Adriamycin-resistant human breast cancer cells
38. Relationship between cytotoxicity, drug accumulation, DNA damage and repair of human ovarian cancer cells treated with doxorubicin: Modulation by tiapamil analog RO11-2933
39. Pharmacological and biological evidence for differing mechanisms of doxorubicin resistance in two human tumor cell lines
40. Detection and analysis of a glucose 6-phosphate dehydrogenase phenotype B cell line contamination
41. Pleiotropic-resistant phenotype is a multifactorial phenomenon in human colon carcinoma cell lines
42. Cytotoxic liponucleotide analogs. II. Antitumor activity of CDP-diacylglycerol analogs containing the cytosine arabinoside moiety
43. CHO mutants resistant to colchicine, colcemid or griseofulvin have an altered β-tubulin
44. New colorimetric cytotoxicity assay for anticancer-drug screening
45. TI GS-164, a small synthetic compound, stimulates tubulin polymerization by a similar mechanism to that of Taxol
46. Eleutherobin, a novel cytotoxic agent that induces tubulin polymerization, is similar to paclitaxel (Taxol)
47. Lack of correlation between expression and function of P-glycoprotein in acute myeloid leukemia cell lines
48. Expression of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells
49. Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype
50. Detection of activity of P-glycoprotein in human tumour samples using rhodamine 123
51. Laser flow cytometry and cancer chemotherapy: Detection of intracellular anthracyclines by flow cytometry
52. Quantitative flow cytometric determination of anthracycline content of rat bone marrow cells
53. Quantification of anthracyclines in human hematopoietic cell subpopulations by flow cytometry and high pressure liquid chromatography
54. Antitumor efficacy of taxane liposomes on a human ovarian tumor xenograft in nude athymic mice
55. Activity of paclitaxel liposome formulations against human ovarian tumor xenografts
56. Implications for clinical pharmacodynamic studies of the statistical characterization of an in vitro antiproliferation assay
57. Combined action of paclitaxel and cisplatin agaist wildtype and resistant human ovarian carcinoma cells
58. Compact numerical method for computers: Linear algebra and function minimization
59. Asymptotically efficient rank invariant test procedures
60. Generation of a drug resistance profile by quantification of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen
61. 2-M arrest and apoptosis in human ovarian cancer cells grown as multicellular tumor spheroids